Genmab’s Tisotumab Vedotin Trial: A Promising Step in Cervical Cancer Treatment

Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.

Genmab, in collaboration with Seagen and other partners, is conducting a Phase 1b/2 open-label trial to evaluate the safety and efficacy of Tisotumab Vedotin, both as a monotherapy and in combination with other cancer agents, for patients with recurrent or stage IVB cervical cancer. The study aims to determine optimal dosing and expand treatment options for this patient group, highlighting its significance in advancing cervical cancer therapies.

The trial tests Tisotumab Vedotin, an antibody-drug conjugate, alone and in combination with Bevacizumab, Pembrolizumab, or Carboplatin. These interventions are intended to improve treatment outcomes for cervical cancer patients who have limited options after standard therapies.

This interventional study is non-randomized with a parallel assignment model and no masking, focusing primarily on treatment. It includes dose escalation and expansion phases to refine dosing strategies.

The study began on February 27, 2019, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 11, 2025, indicating ongoing progress.

The study’s results could influence Genmab’s and its partners’ stock performance, as successful outcomes might enhance their market position in oncology. Investors should watch for updates, considering the competitive landscape in cancer treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.